Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia
Journal of Clinical Medicine · 30.10.2025 · 14 (21) · 7724
DOI: 10.3390/jcm14217724 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 30.10.2025. Verfasst von Anthony Ficany und 4 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, U1144 Optimisation Thérapeutique en Neuropharmacologie (OPTeN), Faculty of Pharmacy, Université Paris-Cité, 75006 Paris, France. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EJP RD COFUND-EJP, AMRO HHT-France, Idex STRATEX.
Abstract (Originalsprache)
Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a vascular disorder with a global prevalence ranging from 1:5000 to 1:8000. It most commonly manifests through nosebleeds, which can be frequent and severe, exposing patients to major iron losses, anemia, and considerable physical and emotional distress. To date, no drug has received the FDA or EMA approval for preventing or treating HHT associated epistaxis, limiting access to therapies and intensifying the burden on patients and clinicians. Based on peer-reviewed evidence, the Second International HHT Guidelines provided a stepwise approach to help physicians manage HHT-related epistaxis highlighting the role of anti-fibrinolytic and systemic antiangiogenic drugs. However, experience from clinical practice and trials indicates marked variability in patient responses, and none of the recommended approaches has demonstrated sufficient placebo-controlled efficacy to gain regulatory approval. Striking insights in HHT physiopathology shed light on complex dysregulated signaling pathways with a triggering role not only by angiogenesis as widely recognized, but also by inflammation, injury and other stimuli, pointing to novel therapeutic targets. This review outlines current recommendations for preventing and managing nosebleeds in HHT patients, highlights the latest insights into the development of telangiectasic lesions, and discusses potential therapeutic treatments currently under clinical investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- INSERM, U1144 Optimisation Thérapeutique en Neuropharmacologie (OPTeN), Faculty of Pharmacy, Université Paris-Cité, 75006 Paris, France.
- ECRIN-European Clinical Research Infrastructure Network, 75014 Paris, France.
- Department of Biomedicine, Centro de Investigaciones Biológicas "Margarita Salas", Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain.
- National Heart and Lung Institute, Imperial College London, London W12 0NN, UK.
- Specialist Medicine, Imperial College Healthcare NHS Trust, London W12 0HS, UK.
ORCID-Profile: Carmelo Bernabeu, Claire L Shovlin, Elisa Rossi
Förderung
- EJP RD COFUND-EJP
- AMRO HHT-France
- Idex STRATEX
- Université Paris Cité and AMRO Foundation
- European Union’s Horizon 2020 research and innovation program
- NIHR Imperial Biomedical Research Centre
Zitieren
APA
Ficany, A., Del Alamo, M., Bernabeu, C., Shovlin, C. L., & Rossi, E. (2025). Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia. Journal of Clinical Medicine, 14(21), 7724. https://doi.org/10.3390/jcm14217724
Vancouver
Ficany A, Del Alamo M, Bernabeu C, Shovlin CL, Rossi E. Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia. Journal of Clinical Medicine. 2025;14(21):7724. doi:10.3390/jcm14217724
BibTeX
@article{Ficany2025,
author = {Ficany, Anthony and Del Alamo, Marta and Bernabeu, Carmelo and Shovlin, Claire L and Rossi, Elisa},
title = {Epistaxis Prevention, Treatment, and Future Perspectives for Hereditary Hemorrhagic Telangiectasia},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {21},
pages = {7724},
doi = {10.3390/jcm14217724}
}
EUVIMED